Product review · Updated September 30, 2026
The INKEY List Salicylic Acid Cleanser: what the pore account measures
A buyer’s nose-pore account, a 66-person consumer trial and an acne label provide different kinds of information.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
The INKEY List’s Salicylic Acid Cleanser has several overlapping stories: an acne-treatment identity, reports of clearer-looking skin and an individual buyer’s account of less noticeable nose pores. Their proximity on a brand website can make them look like one result. This review separates the participants, wording and evidence role behind each story.
The September 30, 2026 examination covers the current 150 mL manufacturer page, a March 7, 2025 US label and bounded passages from the brand’s consumer-results narrative. The full trial report and customers’ skin were not examined. Comfort agreements are reported perceptions here, rather than a measurement of the skin barrier or an assessment of someone’s personal suitability.
In this article
A gel cleanser with an acne-treatment label
The current product page identifies a 150 mL gel cleanser containing 2% salicylic acid. It presents acne, blackheads and oiliness as targets, with zinc and allantoin highlighted in the product story. The US label identifies acne treatment and a rinse-off gel preparation. These records concern this cleanser, rather than every product sold under the brand.
Form and ingredient identity are useful context, but they do not establish which pore feature changed. The format comparison offers a broader reading of that distinction. There is no clinical ranking here between a cleanser and another preparation, or an instruction about how to combine them.
The trial describes 66 people, not a pore-count study
The brand’s consumer-results narrative describes a four-week trial involving 66 people with oily and acne-prone skin. The page calls the trial independent, but this review acquired the brand’s summary, not the underlying report or an independent audit. That attribution matters when considering what the published percentages mean.
The reported answers concern appearance and sensation. They do not supply lesion counts, an observer-rated pore scale or a laboratory measure of oil production. The population description also does not mean that every reader belongs to the tested group. Our claims and visible-pores guide explains why the kind of observation matters as much as an impressive percentage.
Less oily and clearer-looking are separate agreements
In the published trial account, 93% agreed that their skin instantly looked less oily. Another reported agreement says 90% saw visibly clearer skin after three days. The instant oil-appearance answer and the later clarity answer are separate endpoints, even though both appear in the same consumer narrative.
Neither percentage states that 93% or 90% had unclogged pores, fewer acne lesions or a clinically confirmed treatment response. The short durations belong to the reported study observations, not a promised deadline for a reader. The Hero Pore Release review provides another place to examine product-specific wording without treating the two products as equivalent performers.
The nose-pore statement is one buyer’s account
A separate passage in the brand narrative describes a verified buyer, Teigan, who noticed a change in the visibility of pores on the nose and described the cleanser as gentle. That is an individual account. It is not identified as the pore endpoint for the 66-person trial, and its wording cannot supply a percentage for that trial.
A testimonial can show what a person says they noticed while leaving the conditions of observation unknown. The visible-pores and blackheads guide puts that limit in context. This review has not assessed the buyer’s skin, confirmed the cause of the appearance change or generalized that experience to other people.
Comfort does not demonstrate barrier repair
The four-week narrative reports that 92% agreed their skin had not felt tight or stripped during that trial. The product page also emphasizes a comfortable cleansing description. These are relevant to the experience the brand is promising, but they do not report a measured change in barrier function.
Feeling comfortable, appearing less oily and having a less visible pore are three different observations. A consumer answer about tightness cannot be converted into a barrier-repair percentage or proof of universal tolerability. The Bubble serum review is a separate evidence reading, with no suggestion that its participants or comfort findings can be substituted for these cleanser results.
The March label retains a dryness qualification
The March 7, 2025 label, version 5, identifies the Brand Evangelists labeling record and includes a warning about irritation and dryness when another topical acne medication is involved. That warning remains part of the product context alongside never-tight or stripped marketing. It is not resolved by the consumer majority who reported comfort.
FDA’s explanation of Drug Facts fields distinguishes a product’s purpose, uses and warnings. For this cleanser, the acne purpose does not remove the warning, and the warning does not measure pore appearance. A public posting date also does not confirm the version of an individual bottle or establish that every package carries identical current wording.
A defined pore measure would answer a different question
The manufacturer’s trial summary gives useful detail about clarity, oil appearance and comfort, while the buyer story adds a personal nose-pore observation. The missing connection is a defined pore-appearance assessment for the studied cleanser: who was assessed, what feature was scored and how the result was distinguished from an oiliness impression.
The product page also includes an AI-generated review summary, which is a different source genre from a study report. Neither that summary nor the single testimonial fills the measurement gap. The published evidence supports accurately attributed consumer agreements; it does not justify promising a similar pore change or calling the cleanser a clinical winner.
Sources behind this reading
- 2% Salicylic Acid Cleanser for Acne | Oily & Combination Skin | INKEY 150ml ↗Manufacturer exact product, advertising and returned declaration · Checked September 30, 2026
- The INKEY List Salicylic Acid Cleanser ↗Exact manufacturer/labeler OTC labeling record, not approval or inspected package · Checked September 30, 2026
- Salicylic Acid Before & After: Real Acne Results | INKEY ↗Manufacturer-reported 66-person consumer outcomes and separate customer pore account · Checked September 30, 2026
- FDA: reading an OTC Drug Facts label ↗Regulator consumer labeling guidance · Checked September 30, 2026